p53, cancer and the immune response
Open accessAbstract
The importance of cancer-cell-autonomous functions of the tumour suppressor p53 (encoded by TP53) has been established in many studies, but it is now clear that the p53 status of the cancer cell also has a profound impact on the immune response. Loss or mutation of p53 in cancers can affect the recruitment and activity of myeloid and T cells, allowing immune evasion and promoting cancer progression. p53 can also function in immune cells, resulting in various outcomes that can impede or support tumour development. Understanding the role of p53 in tumour and immune cells will help in the development of therapeutic approaches that can harness the differential p53 status of cancers compared with most normal tissue.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mutations can affect the tumor immune microenvironment by altering cytokine expression and regulating the tumor's sensitivity to immune checkpoint inhibitors.
“These mutations can affect the tumor immune microenvironment (TIME) by altering cytokine expression and regulating the tumor’s sensitivity to immune checkpoint inhibitors.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [610]
Gene mutations, including those affecting undruggable proteins, have a significant impact on the efficacy of cancer immunotherapy.
“It is widely accepted that gene mutations, including those affecting undruggable proteins, have a significant impact on the efficacy of cancer immunotherapy.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [610]
Cancer cells with functional wild-type genes tend to have a cancer-restrictive tumor immune microenvironment, while an imbalance in their expression can create a cancer-supportive tumor immune microenvironment.
“For examples, cancer cells with functional wild-type genes tend to have a desirable cancer-restrictive TIME, while an imbalance in their expression can create a cancer-supportive TIME.610,611”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [610]
The status of genes can influence tumor cells through the impact of wild-type gene loss and through their effects on the tumor immune microenvironment.
“In brief, the status of genes can influence tumor cells not only through the impact of wild-type gene loss but also through their effects on the TIME.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [610]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · see citing works
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · see citing works
Helicobacter pylori Infection and the Development of Gastric Cancer
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa001999 · Cited by 4,466 · see citing works
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · see citing works
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · see citing works
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751 · see citing works
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K. R., Signer, S. H., Davidson, N. E., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,730 · see citing works
Hallmarks of Cellular Senescence
Hernandez-Segura, A., Nehme, J., & Demaria, M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.02.001 · Cited by 2,605 · see citing works
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300 · see citing works
A complex secretory program orchestrated by the inflammasome controls paracrine senescence
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J. P., Athineos, D., Kang, T.-W., Lasitschka, F., Andrulis, M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2784 · Cited by 2,278 · see citing works
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,275 · see citing works
Self-citationRegulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,187 · see citing works
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079 · see citing works
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,067 · see citing works
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,057 · see citing works
Senescence of activated stellate cells limits liver fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.06.049 · Cited by 2,029 · see citing works
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993 · see citing works
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.108 · Cited by 1,980 · see citing works
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906 · see citing works
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619 · see citing works
Pathways of Antigen Processing
Blum, J. S., Wearsch, P. A., & Cresswell, P. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095910 · Cited by 1,561 · see citing works
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,553 · see citing works
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms
Li, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,514 · see citing works
Intracellular Toll-like Receptors
Blasius, A. L., & Beutler, B. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.012 · Cited by 1,329 · see citing works
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324 · see citing works
Mutant p53: one name, many proteinsPreprint
Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,246 · see citing works
Mechanisms and functions of cellular senescence
Herranz, N., & Gil, J. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95148 · Cited by 1,232 · see citing works
Hallmarks of cancer: Interactions with the tumor stroma
Pietras, K., & Östman, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.02.045 · Cited by 1,137 · see citing works
Regulation of NF-κB by TNF family cytokines
Hayden, M. S., & Ghosh, S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.05.004 · Cited by 1,116 · see citing works
P53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080 · see citing works
Self-citationSerine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
Maddocks, O. D. K., Berkers, C. R., Mason, S. M., Zheng, L., Blyth, K., Gottlieb, E., & Vousden, K. H. (2013) · Nature · doi:10.1038/nature11743 · Cited by 1,007 · see citing works
Self-citationRegulation of Cutaneous Malignancy by γδ T Cells
Girardi, M., Oppenheim, D. E., Steele, C. R., Lewis, J. M., Glusac, E. J., Filler, R. B., Hobby, P., Sutton, B. J., Tigelaar, R. E., & Hayday, A. (2001) · Science · doi:10.1126/science.1063916 · Cited by 1,002 · see citing works
Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959 · see citing works
Neoantigen-directed immune escape in lung cancer evolution
The TRACERx consortium, Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M., Reading, J. L., et al. (2019) · Nature · doi:10.1038/s41586-019-1032-7 · Cited by 946 · see citing works
Agarwal, M. L., Agarwal, A., Taylor, W. R., & Stark, G. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.18.8493 · Cited by 858 · see citing works
Nelson, W. G., & Kastan, M. B. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1815 · Cited by 850 · see citing works
Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847 · see citing works
Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells
Smyth, M. J., Thia, K. Y. T., Street, S. E. A., Cretney, E., Trapani, J. A., Taniguchi, M., Kawano, T., Pelikan, S. B., Crowe, N. Y., & Godfrey, D. I. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.661 · Cited by 831 · see citing works
Senescence and aging: the critical roles of p53
Rufini, A., Tucci, P., Celardo, I., & Melino, G. (2013) · Oncogene · doi:10.1038/onc.2012.640 · Cited by 798 · see citing works
Non-Cell-Autonomous Tumor Suppression by p53
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766 · cited 1× · see citing works
“This response attracts NK and myeloid cells that can function to remove damaged hepatocytes and so limit fibrosis, cirrhosis and HCC development (Krizhanovsky et al., 2008; Lujambio et al., 2013) (Fig.”
BackgroundPDL1 Regulation by p53 via miR-34
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683 · see citing works
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653 · see citing works
A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity
Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J., & Beach, D. H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1375 · Cited by 649 · see citing works
Graeber, T. G., Peterson, J., Tsai, M., Monica, K., Fornace, A. J., & Giaccia, A. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.9.6264 · Cited by 613 · see citing works
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
Mahadevan, D., & Hoff, D. D. V. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0686 · Cited by 602 · see citing works
Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment
Fu, C., & Jiang, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03059 · Cited by 602 · see citing works
Transcriptional Cross Talk between NF-κB and p53
Webster, G. A., & Perkins, N. D. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3485 · Cited by 598 · see citing works
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592 · see citing works
Leone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt184 · Cited by 553 · see citing works
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553 · see citing works
Linke, S. P., Clarkin, K., Leonardo, A. D., Tsou, A.-P., & Wahl, G. M. (1996) · Genes & Development · doi:10.1101/gad.10.8.934 · Cited by 531 · see citing works
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
Wellenstein, M. D., Coffelt, S. B., Duits, D. E. M., van Miltenburg, M. H., Slagter, M., de Rink, I., Henneman, L., Kas, S. M., Prekovic, S., Hau, C.-S., et al. (2019) · Nature · doi:10.1038/s41586-019-1450-6 · Cited by 500 · see citing works
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246
Cooks, T., Pateras, I. S., Jenkins, L. M. M., Patel, K., Robles, A. I., Morris, J., Forshew, T., Appella, E., Gorgoulis, V. G., & Harris, C. C. (2018) · Nature Communications · doi:10.1038/s41467-018-03224-w · Cited by 483 · see citing works
Hussain, S. P., Amstad, P., Raja, K., Ambs, S., Nagashima, M., Bennett, W. P., Shields, P. G., Ham, A. L., Swenberg, J. A., Marrogi, A. J., et al. (2000) · PubMed · Cited by 482 · see citing works
Matsumoto, Y. M., Marusawa, H., Kinoshita, K., Endo, Y., Kou, T., Morisawa, T., Azuma, T., Okazaki, I., Honjo, T., & Chiba, T. (2007) · Nature Medicine · doi:10.1038/nm1566 · Cited by 480 · see citing works
Cooks, T., Pateras, I. S., Tarcic, O., Solomon, H., Schetter, A. J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rozenfeld, N., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.022 · Cited by 471 · see citing works
Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444 · see citing works
黒瀬, 圭., Gilley, K., Matsumoto, S., Watson, P. H., Zhou, X.-P., & Eng, C. (2002) · Nature Genetics · doi:10.1038/ng1013 · Cited by 418 · see citing works
Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130783 · Cited by 414 · see citing works
Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells
Keates, S. E., Hitti, Y., Upton, M. P., & Kelly, C. P. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9322504 · Cited by 414 · see citing works
Role of Stat3 in Regulating p53 Expression and Function
Niu, G., Wright, K. L., Ma, Y., Wright, G. M., Huang, M., Irby, R., Briggs, J., Karras, J. G., Cress, W. D., Pardoll, D. M., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7432-7440.2005 · Cited by 398 · see citing works
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., et al. (2014) · Nature · doi:10.1038/nature13638 · Cited by 388 · see citing works
Lacroix, M., Riscal, R., Arena, G., Linares, L. K., & Cam, L. L. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.10.002 · Cited by 367 · see citing works
Ren, G., Zhao, X., Wang, Y., Zhang, X., Chen, X., Xu, C., Yuan, Z.-R., Roberts, A. I., Zhang, L., Zheng, H. B., et al. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.08.013 · Cited by 363 · see citing works
DiLillo, D. J., Yanaba, K., & Tedder, T. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903009 · Cited by 361 · see citing works
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation
Hofseth, L. J., Saito, S., Hussain, S. P., Espey, M. G., Miranda, K. M., Araki, Y., Jhappan, C., Higashimoto, Y., He, P., Linke, S. P., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237083100 · Cited by 355 · see citing works
Biton, J., Mansuet‐Lupo, A., Pécuchet, N., Alifano, M., Ouakrim, H., Arrondeau, J., Boudou, P., Goldwasser, F., Leroy, K., Goc, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0163 · Cited by 353 · see citing works
NKG2D function protects the host from tumor initiation
Smyth, M. J., Swann, J. B., Cretney, E., Zerafa, N., Yokoyama, W. M., & Hayakawa, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050994 · Cited by 344 · see citing works
Immunological Surveillance in Neoplasia
Burnet, F. M. (1971) · Immunological Reviews · doi:10.1111/j.1600-065x.1971.tb00461.x · Cited by 343 · see citing works
Selective Evolution of Stromal Mesenchyme with p53 Loss in Response to Epithelial Tumorigenesis
Hill, R., Song, Y., Cardiff, R. D., & Van Dyke, T. (2005) · Cell · doi:10.1016/j.cell.2005.09.030 · Cited by 324 · see citing works
Serum p53 antibodies as early markers of lung cancer
Lubin, R., Zalcman, G., Bouchet, L., Trédaniel, J., Legros, Y., Cazals-Hatem, D. L., Hirsch, A., & Soussi, T. (1995) · Nature Medicine · doi:10.1038/nm0795-701 · Cited by 317 · see citing works
Kim, M. P., & Lozano, G. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.185 · Cited by 313 · see citing works
Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302 · cited 1× · see citing works
“The SASP molecules can attract both anti- and pro-tumorigenic immune populations, depending on the cancer type and mechanism of senescence (Coppé et al., 2008; Herranz and Gil, 2018).”
BackgroundBreast-Cancer Stromal Cells with TP53 Mutations and Nodal Metastases
Patócs, A., Zhang, L., Xu, Y., Weber, F., Caldés, T., Mutter, G. L., Platzer, P., & Eng, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071825 · Cited by 297 · see citing works
The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting
Fingerle‐Rowson, G., Petrenko, O., Metz, C. N., Forsthuber, T. G., Mitchell, R. A., Huss, R., Moll, U. M., Müller, W., & Bucala, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533295100 · Cited by 284 · see citing works
Wörmann, S. M., Song, L., Ai, J., Diakopoulos, K. N., Kurkowski, M. U., Görgülü, K., Ruess, D. A., Campbell, A. D., Doglioni, C., Jodrell, D. I., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.010 · Cited by 276 · see citing works
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.
Davidoff, A. M., Iglehart, J. D., & Marks, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3439 · Cited by 276 · see citing works
Schlichtholz, B., Legros, Y., Gillet, D., Fruchart‐Gaillard, C., Marty, M. E., Lane, D. P., Calvo, F. M., & Soussi, T. (1992) · PubMed · Cited by 276 · see citing works
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Malekzadeh, P., Pasetto, A., Robbins, P. F., Parkhurst, M. R., Paria, B. C., Jia, L., Gartner, J. J., Hill, V. K., Yu, Z., Restifo, N. P., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123791 · Cited by 274 · see citing works
Ponzetta, A., Carriero, R., Carnevale, S., Barbagallo, M., Molgora, M., Perucchini, C., Magrini, E. I., Gianni, F., Kunderfranco, P., Polentarutti, N., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.047 · Cited by 257 · see citing works
Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.
Mayordomo, J. I., Loftus, D. J., Sakamoto, H., Cesare, C. M. D., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., & DeLeo, A. B. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.4.1357 · Cited by 253 · see citing works
p53 is a suppressor of inflammatory response in mice
Komarova, E. A., Krivokrysenko, V. I., Wang, K., Neznanov, N. S., Chernov, M. V., Komarov, P. G., Brennan, M., Golovkina, T. V., Rokhlin, O. W., Kuprash, D. V., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3213fje · Cited by 243 · see citing works
Walton, J. B., Blagih, J., Ennis, D. P., Leung, E. Y. L., Dowson, S., Farquharson, M., Tookman, L. A., Orange, C., Athineos, D., Mason, S. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1272 · Cited by 232 · see citing works
Self-citationA Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3
Tajan, M., Hock, A. K., Blagih, J., Robertson, N. A., Labuschagne, C. F., Kruiswijk, F., Humpton, T. J., Adams, P. D., & Vousden, K. H. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.005 · Cited by 230 · see citing works
Self-citationDeconstructing networks of p53-mediated tumor suppression in vivo
Kaiser, A. M., & Attardi, L. D. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.171 · Cited by 227 · see citing works
Interleukin 6 Supports the Maintenance of p53 Tumor Suppressor Gene Promoter Methylation
Hodge, D. R., Peng, B. H., Cherry, J. C., Hurt, E. M., Fox, S. D., Kelley, J. A., Munroe, D. J., & Farrar, W. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3589 · Cited by 226 · see citing works
Candido, J. B., Morton, J. P., Bailey, P., Campbell, A. D., Karim, S. A., Jamieson, T., Lapienyte, L., Gopinathan, A., Clark, W., McGhee, E. J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.131 · Cited by 224 · see citing works
Textor, S., Fiegler, N., Arnold, A., Porgador, A., Hofmann, T. G., & Cerwenka, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3211 · Cited by 221 · see citing works
Neutrophil-induced genomic instability impedes resolution of inflammation and wound healing
Butin‐Israeli, V., Bui, T. M., Wiesolek, H. L., Mascarenhas, L., Lee, J. J., Mehl, L. C., Knutson, K. R., Adam, S. A., Goldman, R. D., Beyder, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122085 · Cited by 221 · see citing works
Control of metabolism by p53 – Cancer and beyond
Labuschagne, C. F., Zani, F., & Vousden, K. H. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.06.001 · Cited by 219 · see citing works
Self-citationThe Macrophage Colony-Stimulating Factor 1 Response Signature in Breast Carcinoma
Beck, A. H., Espinosa, Í., Edris, B., Li, R., Montgomery, K. D., Zhu, S., Varma, S., Marinelli, R. J., van de Rijn, M., & West, R. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1283 · Cited by 210 · see citing works
On immunosurveillance in human cancer.
Thomas, L. (1983) · PubMed · Cited by 210 · see citing works
Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes
Vierboom, M., Nijman, H. W., Offringa, R., van der Voort, E. I. H., van Hall, T., van den Broek, L., Fleuren, G. J., Kenemans, P., Kast, W. M., & Melief, C. J. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.695 · Cited by 206 · see citing works
Wnt signaling is required for thymocyte development and activates Tcf-1 mediated transcription
Staal, F. J. T., Meeldijk, J., Moerer, P., Jay, P., van de Weerdt, B. C. M., Vainio, S. J., Nolan, G. P., & Clevers, H. C. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200101)31:1 · Cited by 200 · see citing works
Mutant p53 Enhances Nuclear Factor κB Activation by Tumor Necrosis Factor α in Cancer Cells
Weisz, L., Damalas, A., Liontos, M., Karakaidos, P., Fontemaggi, G., Maor-Aloni, R., Kalis, M. L., Levrero, M., Strano, S., Gorgoulis, V. G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2425 · Cited by 198 · see citing works
Heinemann, A., Zhao, F., Pechlivanis, S., Eberle, J., Steinle, A., Diederichs, S., Schadendorf, D., & Paschen, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1977 · Cited by 187 · see citing works
Current issues and perspectives in PD-1 blockade cancer immunotherapy
Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 180 · see citing works
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms
Bezzi, M., Seitzer, N., Ishikawa, T., Reschke, M., Chen, M., Wang, G., Mitchell, C., Ng, C., Katon, J. M., Lunardi, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4463 · Cited by 175 · see citing works
A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
Noguchi, Y., Chen, Y., & Old, L. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3171 · Cited by 173 · see citing works
p53 and NF-κB Coregulate Proinflammatory Gene Responses in Human Macrophages
Lowe, J. M., Menéndez, D., Bushel, P. R., Shatz, M., Kirk, E. L., Troester, M. A., Garantziotis, S., Fessler, M. B., & Resnick, M. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1070 · Cited by 170 · see citing works
Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses
Blagih, J., Zani, F., Chakravarty, P., Hennequart, M., Pilley, S. E., Hobor, S., Hock, A. K., Walton, J. B., Morton, J. P., Gronroos, E. C., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.028 · Cited by 170 · see citing works
Self-citationGuo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2832 · Cited by 168 · see citing works
A unique role for p53 in the regulation of M2 macrophage polarization
Li, L., Ng, D. S. W., Mah, W.-C., Almeida, F. F., Rahmat, S. A. B., Rao, V. K., Leow, S. C., Laudisi, F., Peh, M. T., Goh, A. M., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.212 · Cited by 166 · see citing works
Ehrlich, P. F. (1913) · BMJ · doi:10.1136/bmj.2.2746.353 · Cited by 161 · see citing works
Cha, Y. J., Kim, H. R., Lee, C. Y., Cho, B. C., & Shim, H. S. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.001 · Cited by 157 · see citing works
Brazil, J. C., Louis, N. A., & Parkos, C. A. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318281f54e · Cited by 157 · see citing works
p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300.
Ravi, R. K., Mookerjee, B., van Hensbergen, Y., Bedi, G. C., Giordano, A., El‐Deiry, W. S., Fuchs, E. J., & Bedi, A. (1998) · PubMed · Cited by 156 · see citing works
p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1
Wang, B., Niu, D., Lai, L., & Ren, E. C. (2013) · Nature Communications · doi:10.1038/ncomms3359 · Cited by 154 · see citing works
Kitamura, T., Doughty-Shenton, D., Cassetta, L., Fragkogianni, S., Brownlie, D., Kato, Y., Carragher, N. O., & Pollard, J. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.02004 · Cited by 148 · see citing works
Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer
Vivian Goodell, A., Salazar, L. G., Urban, N. D., Drescher, C. W., Gray, H. J., Swensen, R. E., McIntosh, M. W., & Disis, M. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2813 · Cited by 145 · see citing works
Shatz, M., Menendez, D., & Resnick, M. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4134 · Cited by 143 · see citing works
SOCS1 Links Cytokine Signaling to p53 and Senescence
Calabrese, V., Mallette, F. A., Deschênes‐Simard, X., Ramanathan, S., Gagnon, J., Moores, A., Ilangumaran, S., & Ferbeyre, G. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.044 · Cited by 141 · see citing works
Tumor Suppressor p53 Inhibits Autoimmune Inflammation and Macrophage Function
Zheng, S. J., Lamhamedi-Cherradi, S.-E., Wang, P., Xu, L., & Chen, Y. H. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1423 · Cited by 141 · see citing works
Leffers, N., Lambeck, A. J. A., Gooden, M. J. M., Hoogeboom, B. N., Wolf, R., Hamming, I. L. E., Hepkema, B. G., Willemse, P. H. B., Molmans, B. H. W., Hollema, H., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24597 · Cited by 141 · see citing works
Antibodies against p53 are associated with poor prognosis of colorectal cancer
Houbiers, J. G. A., van der Burg, S., van de Watering, L., Tollenaar, R., Brand, A., van de Velde, C., & Melief, C. J. M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.386 · Cited by 141 · see citing works
CCR5 Expression Influences the Progression of Human Breast Cancer in a p53-dependent Manner
Mañes, S., Mira, E., Colomer, R., Montero, S., Real, L. M., Gómez‐Moutón, C., Jiménez-Baranda, S., Garzón, A., Lacalle, R. A., Harshman, K., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030580 · Cited by 140 · see citing works
NKG2D signaling in cancer immunosurveillance
López‐Soto, A., Huergo-Zapico, L., Acebes‐Huerta, A., Villa-Álvarez, M., & Gonzalez, S. R. (2014) · International Journal of Cancer · doi:10.1002/ijc.28775 · Cited by 136 · see citing works
Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT
Leszczyńska, K. B., Foskolou, I. P., Abraham, A., Anbalagan, S., Tellier, C., Haider, S. A., Span, P. N., O’Neill, E. E., Buffa, F. M., & Hammond, E. M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80402 · Cited by 129 · see citing works
p53 induces TAP1 and enhances the transport of MHC class I peptides
Zhu, K., Wang, J., Zhu, J., Jiang, J., Shou, J., & Chen, X. (1999) · Oncogene · doi:10.1038/sj.onc.1203235 · Cited by 121 · see citing works
p53: emerging roles in stem cells, development and beyond
Jain, A. K., & Barton, M. C. (2018) · Development · doi:10.1242/dev.158360 · Cited by 121 · see citing works
Li, H., Lakshmikanth, T., Garofalo, C., Enge, M., Spinnler, C., Anichini, A., Székely, L., Kärre, K., Carbone, E., & Selivanova, G. (2011) · Cell Cycle · doi:10.4161/cc.10.19.17630 · Cited by 120 · see citing works
Sharma, M. D., Rodrı́guez, P. C., Koehn, B. H., Baban, B., Cui, Y. R., Guo, G., Shimoda, M., Pacholczyk, R., Shi, H., Lee, E.-J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.014 · Cited by 119 · see citing works
Photobleaching of protoporphyrin IX in cells incubated with 5-aminolevulinic acid
Moan, J. E., Streckytė, G., Bagdonas, S., Gadmar, Ø. B., & Berg, K. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970106)70:1 · Cited by 118 · see citing works
Roth, J., Dittmer, D. P., Réa, D., Tartaglia, J., Paoletti, E., & Levine, A. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4781 · Cited by 118 · see citing works
Pathologies Associated with the p53 ResponsePreprint
Gudkov, A. V., & Komarova, E. A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001180 · Cited by 116 · see citing works
Policing of oncogene activity by p53
Efeyan, A., Garcı́a-Cao, I., Herranz, D., Velasco-Miguel, S., & Serrano, M. (2006) · Nature · doi:10.1038/443159a · Cited by 114 · see citing works
Hernández, J., Lee, P. P., Davis, M. M., & Sherman, L. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.596 · Cited by 110 · see citing works
p53 Status in Stromal Fibroblasts Modulates Tumor Growth in an SDF1-Dependent Manner
Addadi, Y., Moskovits, N. B.-C., Granot, D., Lozano, G., Carmi, Y., Apte, R. N., Neeman, M., & Oren, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1146 · Cited by 108 · see citing works
Mehta, S., Christopherson, K. W., Bhat‐Nakshatri, P., Goulet, R. J., Broxmeyer, H. E., Kopelovich, L., & Nakshatri, H. (2006) · Oncogene · doi:10.1038/sj.onc.1210120 · Cited by 107 · see citing works
Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling
Rahnamoun, H., Lu, H., Duttke, S. H. C., Benner, C. W., Glass, C. K., & Lauberth, S. M. (2017) · Nature Communications · doi:10.1038/s41467-017-01117-y · Cited by 103 · see citing works
Hoffmann, T. K., Donnenberg, A. D., Finkelstein, S. D., Donnenberg, V. S., Friebe-Hoffmann, U., Myers, E. N., Appella, E., DeLeo, A. B., & Whiteside, T. L. (2002) · PubMed · Cited by 103 · see citing works
Lin, J., Tang, H., Jin, X., Jia, G., & Hsieh, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205426 · Cited by 101 · see citing works
Watanabe, M., Moon, K. D., Vacchio, M. S., Hathcock, K. S., & Hodes, R. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.006 · Cited by 98 · see citing works
P53 and The Immune Response: 40 Years of Exploration—A Plan for the Future
Levine, A. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020541 · Cited by 97 · see citing works
Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study
Vermeij, R., Leffers, N., Hoogeboom, B. N., Hamming, I. L. E., Wolf, R., Reyners, A. K. L., Molmans, B. H. W., Hollema, H., Bart, J., Drijfhout, J. W., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27388 · Cited by 97 · see citing works
Schauer, I. G., Zhang, J., Xing, Z., Guo, X. Q., Mercado‐Uribe, I., Sood, A. K., Huang, P., & Liu, J. (2013) · Neoplasia · doi:10.1593/neo.121228 · Cited by 97 · see citing works
Hoffmann, T. K., Nakano, K., Elder, E. M., Dworacki, G., Finkelstein, S. D., Appella, E., Whiteside, T. L., & DeLeo, A. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5938 · Cited by 91 · see citing works
van der Burg, S. H., Menon, A. G., Redeker, A., Bonnet, M.-C., Drijfhout, J. W., Tollenaar, R. A. �. �., van de Velde, C. J. �., Moingeon, P. E., Kuppen, P. J. K., Offringa, R., et al. (2002) · PubMed · Cited by 90 · see citing works
Role of toll-like receptors in tissue repair and tumorigenesis
Rakoff-Nahoum, S., & Medzhitov, R. M. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908050088 · Cited by 89 · see citing works
Dijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Nijman, H. W., van Poelgeest, M. I. E., van Erkel, A. R., Smit, V. T. H. B. M., Daemen, T., van der Hoeven, J. J. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4772 · Cited by 83 · see citing works
Tumor Suppressor p53 Inhibits Systemic Autoimmune Diseases by Inducing Regulatory T Cells
Kawashima, H., Takatori, H., Suzuki, K., Iwata, A., Yokota, M., Suto, A., Minamino, T., Hirose, K., & Nakajima, H. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300509 · Cited by 83 · see citing works
Nowak, D. G., Cho, H., Herzka, T. M., Watrud, K. E., DeMarco, D. V., Wang, V. M.-Y., Şentürk, Ş., Fellmann, C., Ding, D., Beinortas, T., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1113 · Cited by 80 · see citing works
Espenschied, J. R., Lamont, J., Longmate, J., Pendas, S., Wang, Z., Diamond, D. J., & Ellenhorn, J. D. I. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3401 · Cited by 78 · see citing works
Tran, T. Q., Lowman, X. H., Reid, M. A., Mendez‐Dorantes, C., Pan, M., Yang, Y., & Kong, M. (2016) · Oncogene · doi:10.1038/onc.2016.360 · Cited by 77 · see citing works
Ubertini, V, Norelli, G., D'Arcangelo, D., Gurtner, A., Cesareo, E., Baldari, S., Gentileschi, M. P., Piaggio, G., Nisticò, P., Soddu, S., et al. (2015) · Oncogene · doi:10.1038/onc.2014.191 · Cited by 75 · see citing works
Campregher, C., Luciani, M. G., & Gasché, C. (2008) · Gut · doi:10.1136/gut.2007.141556 · Cited by 73 · see citing works
Volkmann, M., Müller, M., Hofmann, W. J., Meyer, M., Hagelstein, J., Räth, U., Kommerell, B., Zentgraf, H., & Galle, P. R. (1993) · Hepatology · doi:10.1002/hep.1840180313 · Cited by 70 · see citing works
Guo, G., Marrero, L., Rodrı́guez, P. C., Valle, L. D., Ochoa, A. C., & Cui, Y. R. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3810 · Cited by 69 · see citing works
Regulatory role of p53 in experimental autoimmune encephalomyelitis
Okuda, Y., Okuda, M., & Bernard, C. C. A. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00428-9 · Cited by 69 · see citing works
Huang, Y., Yu, P., Li, W., Ren, G., Roberts, A. I., Cao, W., Zhang, X., Su, J., Chen, X., Chen, Q., et al. (2013) · Oncogene · doi:10.1038/onc.2013.355 · Cited by 68 · see citing works
Hardwick, N. R., Frankel, P., Ruel, C., Kilpatrick, J., Tsai, W., Kos, F., Kaltcheva, T., Leong, L., Morgan, R., Chung, V., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2709 · Cited by 66 · see citing works
Chiappori, A. A., Williams, C. C., Gray, J. E., Tanvetyanon, T., Haura, E. B., Creelan, B. C., Thapa, R., Chen, D.-T., Simon, G. R., Bepler, G., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2287-9 · Cited by 64 · see citing works
He, X., Xiang, C., Zhang, C.-X., Xie, Y., Chen, L., Zhang, G.-X., Lu, Y., & Liu, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.045 · Cited by 62 · see citing works
Long‐term clinical and immunological effects of p53‐SLP® vaccine in patients with ovarian cancer
Leffers, N., Vermeij, R., Hoogeboom, B., Schulze, U. R., Wolf, R., Hamming, I. E., van der Zee, A. G., Melief, K. J., van der Burg, S. H., Daemen, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.25980 · Cited by 60 · see citing works
Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.
Zwaveling, S., Vierboom, M., Mota, S. C. F., Hendriks, J. A., Ooms, M. E., Sutmuller, R. P. M., Franken, K. L. M. C., Nijman, H. W., OSSENDORP, F. A., van der Burg, S. H., et al. (2002) · PubMed · Cited by 60 · see citing works
p53‐mediated adaptation to serine starvation is retained by a common tumour‐derived mutant
Humpton, T. J., Hock, A. K., Maddocks, O. D. K., & Vousden, K. H. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0191-6 · Cited by 58 · see citing works
Self-citationZambetti, G. P., Olson, D., Labow, M., & Levine, A. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3952 · Cited by 57 · see citing works
Kennedy, S. R., Zhang, Y., & Risques, R. A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.007 · Cited by 56 · see citing works
Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth
Narendran, A., Ganjavi, H., Morson, N., Connor, A. M., Barlow, J. W., Keystone, E. C., Malkin, D. M., & Freedman, M. H. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00159-0 · Cited by 56 · see citing works
Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen
Lauwen, M. M., Zwaveling, S., de Quartel, L., Mota, S. C. F., Grashorn, J. C., Melief, C. J. M., van der Burg, S. H., & Offringa, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3166 · Cited by 54 · see citing works
p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis
Ruddell, A., Kelly‐Spratt, K. S., Furuya, M. H., Parghi, S. S., & Kemp, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210973 · Cited by 53 · see citing works
Translocation of the p53 gene in t(15;17) in acute promyelocytic leukaemia
Beau, M. M. L., Westbrook, C. A., Dı́az, M. O., Rowley, J. D., & Oren, M. (1985) · Nature · doi:10.1038/316826a0 · Cited by 53 · see citing works
Long story short: p53 mediates innate immunity
Miciak, J. J., & Bunz, F. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.001 · Cited by 49 · see citing works
p53-dependent expression of CXCR5 chemokine receptor in MCF-7 breast cancer cells
Mitkin, N. A., Hook, C., Schwartz, A. M., Biswas, S., Кочетков, Д. В., Muratova, A. M., Afanasyeva, M., Kravchenko, J. E., Bhattacharyya, A., & Kuprash, D. V. (2015) · Scientific Reports · doi:10.1038/srep09330 · Cited by 49 · see citing works
Menon, A. G., Kuppen, P. J. K., van der Burg, S. H., Offringa, R., Bonnet, M.-C., Harinck, B. I. J., Tollenaar, R. A. �. �., Redeker, A., Putter, H., Moingeon, P. E., et al. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700600 · Cited by 49 · see citing works
Trp53 negatively regulates autoimmunity via the STAT3‐Th17 axis
Zhang, S., Zheng, M., Kibe, R., Huang, Y., Marrero, L., Warren, S., Zieske, A. W., Iwakuma, T., Kolls, J. K., & Cui, Y. R. (2011) · The FASEB Journal · doi:10.1096/fj.10-175299 · Cited by 48 · see citing works
Daftarian, P. M., Song, G.-Y., Ali, S., Faynsod, M., Longmate, J., Diamond, D. J., & Ellenhorn, J. D. I. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0169 · Cited by 48 · see citing works
Lack of p53 Augments Antitumor Functions in Cytolytic T Cells
Banerjee, A., Thyagarajan, K., Chatterjee, S., Chakraborty, P., Kesarwani, P., Soloshchenko, M., Al-Hommrani, M., Andrijauskaite, K., Moxley, K. M., Janakiraman, H., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1798 · Cited by 37 · see citing works
Lambeck, A. J. A., Leffers, N., Hoogeboom, B. N., Sluiter, W. J., Hamming, I. L. E., Klip, H. G., ten Hoor, K. A., Esajas, M. D., van Oven, M., Drijfhout, J. W., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22710 · Cited by 34 · see citing works
Couch, M. E., Ferris, R. L., Brennan, J. A., Koch, W. M., Jaffee, E. M., Leibowitz, M. S., Nepom, G. T., Erlich, H. A., & Sidransky, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0682 · Cited by 34 · see citing works
Control mechanisms in germ cells mediated by p53 family proteins
Gebel, J., Tuppi, M., Krauskopf, K., Coutandin, D., Pitzius, S., Kehrloesser, S., Osterburg, C., & Dötsch, V. (2017) · Journal of Cell Science · doi:10.1242/jcs.204859 · Cited by 33 · see citing works
Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells
Menendez, D., Lowe, J. M., Snipe, J., & Resnick, M. A. (2016) · Oncotarget · doi:10.18632/oncotarget.11210 · Cited by 31 · see citing works
CD4+ T Cell Responses to Self- and Mutated p53 Determinants During Tumorigenesis in Mice
Fedoseyeva, E. V., Boisgérault, F., Anosova, N. G., Wollish, W., Arlotta, P., Jensen, P. E., Ono, S. J., & Bénichou, G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.11.5641 · Cited by 30 · see citing works
Angelopoulou, K., & Diamandis, E. P. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00295-x · Cited by 30 · see citing works
Shatz, M., Shats, I., Menendez, D., & Resnick, M. A. (2015) · Oncotarget · doi:10.18632/oncotarget.4435 · Cited by 29 · see citing works
Absence of p53 autoantibodies in sera from glioma patients.
Rainov, N. G., Dobberstein, K.-U., Fittkau, M., Bahn, H., Holzhausen, H. ‐., Gantchev, L. S., & Burkert, W. L. (1995) · PubMed · Cited by 24 · see citing works
Natural killer cells limit the clearance of senescent lung adenocarcinoma cells
Stokes, K. L., Cortez-Retamozo, V., Acosta, J., Lauderback, B., Robles-Oteiza, C., Cicchini, M., Pittet, M. J., & Feldser, D. M. (2019) · Oncogenesis · doi:10.1038/s41389-019-0133-3 · Cited by 21 · see citing works
Repression of the minimal hla-b promoter by c-myc and p53 occurs through independent mechanisms
Griffioen, M., Steegenga, W. T., Ouwerkerk, I. J. M., Peltenburg, L. T. C., Jochemsen, A. G., & Schrier, P. I. (1998) · Molecular Immunology · doi:10.1016/s0161-5890(98)00074-1 · Cited by 20 · see citing works
Sabapathy, K., & Nam, S. Y. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.55 · Cited by 19 · see citing works
Abdel‐Rahman, W. M., Aravind, S. R., Nair, V. A., Bajbouj, K., Valo, S., & Peltomäki, P. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-eacr25.46 · Cited by 19 · see citing works
Li, D., Hu, M., Liu, Y., Du, P., Du, P., Li, C.-S., Cheng, L., Liu, P., Jiang, J., Su, L., et al. (2018) · Cell Discovery · doi:10.1038/s41421-017-0007-9 · Cited by 18 · see citing works
Humoral immune response to p53 in malignant glioma
Weller, M., Ständer, M., Schabet, M., DICHGANS, J., Bornemann, A., & Meyermann, R. (1998) · Journal of Neurology · doi:10.1007/s004150050199 · Cited by 16 · see citing works
Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche
Pantziarka, P. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.541 · Cited by 15 · see citing works
Albers, A. E., Qian, X., Kaufmann, A. M., Mytilineos, D., Ferris, R. L., Hoffmann, T. K., & DeLeo, A. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-29067-5 · Cited by 10 · see citing works
Flagged first, then by citations
6 of the 195 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 0b013e318281f54e · DOI
Cited by
Sorted by citations
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 736 · see citing works
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 519 · see citing works
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494 · see citing works
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 339 · see citing works
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 279 · see citing works
Xiao, Y., Chen, J., Zhou, H., Zeng, X., Ruan, Z., Pu, Z., Jiang, X., Matsui, A., Zhu, L., Amoozgar, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28279-8 · Cited by 267 · see citing works
The complexity of p53-mediated metabolic regulation in tumor suppression
Liu, Y., & Gu, W. J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.010 · Cited by 260 · see citing works
Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches
Alvarado-Ortiz, E., de la Cruz-López, K. G., Becerril-Rico, J., Sarabia-Sánchez, M. Á., Ortíz-Sánchez, E., & García-Carrancá, A. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607670 · Cited by 189 · see citing works
Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 173 · see citing works
Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation
Ren, F., Fei, Q., Qiu, K. L., Zhang, Y., Zhang, H., & Sun, L. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03026-7 · Cited by 169 · see citing works
Shouval, R., Tomas, A. A., Fein, J. A., Flynn, J. R., Markovits, E., Mayer, S., Afuye, A. O., Alperovich, A., Anagnostou, T., Besser, M. J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.02143 · Cited by 155 · see citing works
DNA Replication Stress and Chromosomal Instability: Dangerous Liaisons
Wilhelm, T., Said, M., & Naim, V. (2020) · Genes · doi:10.3390/genes11060642 · Cited by 150 · see citing works
A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies
Thapa, R., Gupta, G., Bhat, A. A., Almalki, W. H., Alzarea, S. I., Kazmi, I. A., Saleem, S., Khan, R., Altwaijry, N., Dureja, H., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127375 · Cited by 139 · see citing works
Maddalena, M., Mallel, G., Nataraj, N. B., Shreberk‐Shaked, M., Hassin, O., Mukherjee, S., Arandkar, S., Rotkopf, R., Kapsack, A., Lambiase, G., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025631118 · Cited by 114 · see citing works
The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
Michel, M. S., Kaps, L., Maderer, A., Galle, P. R., & Moehler, M. H. (2021) · Cancers · doi:10.3390/cancers13102296 · Cited by 113 · see citing works
Sun, Z., Zhao, Y., Yan, W., Ding, X., Tan, C., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.939523 · Cited by 104 · see citing works
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 97 · see citing works
The role of p53 in anti-tumor immunity and response to immunotherapy
Carlsen, L., Zhang, S., Tian, X., Cruz, A. D. L., George, A., Arnoff, T. E., & El‐Deiry, W. S. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1148389 · Cited by 92 · see citing works
Awasthi, S., Berglund, A., Abraham-Miranda, J., Rounbehler, R. J., Kensler, K. H., Serna, A. N., Vidal, A. C., You, S., Freeman, M. R., Davicioni, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2925 · Cited by 86 · see citing works
Bröske, A.-M. E., Korfi, K., Belousov, A., Wilson, S., Ooi, C.-H., Bolen, C. R., Cañamero, M., Alcaide, E. G., James, I., Piccione, E. C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005954 · Cited by 84 · see citing works
A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development
Shi, D., & Jiang, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.762651 · Cited by 81 · see citing works
Recent Progress in Biosensors for Detection of Tumor Biomarkers
Li, M., Jiang, F., Xue, L., Peng, C. Y., Shi, Z., Zhang, Z., Li, J., Pan, Y., Wang, X., Feng, C., et al. (2022) · Molecules · doi:10.3390/molecules27217327 · Cited by 73 · see citing works
p53 at the crossroads of tumor immunity
Efe, G., Rustgi, A. K., & Prives, C. L. (2024) · Nature Cancer · doi:10.1038/s43018-024-00796-z · Cited by 81 · see citing works
Hároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 71 · see citing works
DDX5 and DDX17—multifaceted proteins in the regulation of tumorigenesis and tumor progression
Xu, K., Sun, S., Yan, M., Cui, J., Yang, Y., Li, W., Huang, X., Dou, L., Chen, B., Tang, W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.943032 · Cited by 64 · see citing works
Takahashi, S., Fujiwara, Y., Nakano, K., Shimizu, T., Tomomatsu, J., Koyama, T., Ogura, M., Tachibana, M., Kakurai, Y., Yamashita, T., et al. (2021) · Cancer Science · doi:10.1111/cas.14875 · Cited by 60 · see citing works
Baba, R. E., & Herbein, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730765 · Cited by 66 · see citing works
Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer
Luo, X., Xu, J., Yu, J., & Yi, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.692360 · Cited by 55 · see citing works
Environmental and Lifestyle Risk Factors in the Carcinogenesis of Gallbladder Cancer
Pérez, P. E., Riquelme, I., García, P., Brebi, P., & Roa, J. C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020234 · Cited by 55 · see citing works
Wang, T., Zhou, Y., Zhou, Z., Zhang, P., Yan, R., Sun, L., Ma, W., Zhang, T., Shen, S., Liu, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37227-z · Cited by 55 · see citing works
Mutant p53 in cell-cell interactionsPreprint
Pilley, S. E., Rodríguez, T. A., & Vousden, K. H. (2021) · Genes & Development · doi:10.1101/gad.347542.120 · Cited by 54 · see citing works
Self-citationExpanding the Spectrum of Adenoviral Vectors for Cancer Therapy
Gao, J. J., Zhang, W., & Ehrhardt, A. (2020) · Cancers · doi:10.3390/cancers12051139 · Cited by 54 · see citing works
Cheshomi, H., Bahrami, A. R., Rafatpanah, H., & Matin, M. M. (2022) · Human & Experimental Toxicology · doi:10.1177/09603271211064534 · Cited by 50 · see citing works
Xie, Y., Zhou, T., Li, X., Zhao, K., Bai, W., Hou, X., Liu, Z., Ni, B., Zhang, Z., Yan, J., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.02.046 · Cited by 49 · see citing works
Understanding the cellular origin and progression of esophageal cancer using esophageal organoids
Sachdeva, U. M., Shimonosono, M., Flashner, S. P., Cruz‐Acuña, R., Gabre, J. T., & Nakagawa, H. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.031 · Cited by 47 · see citing works
Anti-Tumor Effects of Chinese Medicine Compounds by Regulating Immune Cells in Microenvironment
Chen, F., Li, J., Wang, H., & Ba, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.746917 · Cited by 47 · see citing works
Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity
Mansouri, S., Heylmann, D., Stiewe, T., Kracht, M., & Savai, R. (2022) · eLife · doi:10.7554/elife.79895 · Cited by 45 · see citing works
Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma
Shi, Y., Xie, T., Wang, B., Wang, R., Cai, Y., Yuan, B., Gleber‐Netto, F. O., Tian, X., Rodriguez-Rosario, A. E., Osman, A. A., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03675-4 · Cited by 45 · see citing works
Fang, Y., Zhang, M., He, Y., Li, C., Fang, H., Xu, P., Cheng, S., Zhao, Y. F., Feng, Y., Liu, Q., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01626-x · Cited by 45 · see citing works
Breathing new insights into the role of mutant p53 in lung cancer
Chen, T., Ashwood, L. M., Kondrashova, O., Strasser, A., Kelly, G. L., & Sutherland, K. D. (2024) · Oncogene · doi:10.1038/s41388-024-03219-6 · Cited by 44 · see citing works
Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy
Chasov, V. V., Mirgayazova, R., Zmievskaya, E., Khadiullina, R., Valiullina, A., Clarke, J. R. S., Rizvanov, A. A., Baud, M. G. J., & Bulatov, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01460 · Cited by 42 · see citing works
Zhang, Z., Zhang, W., Wang, Y., Wan, T., Hu, B., Li, C., Ge, X., & Lu, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.792676 · Cited by 42 · see citing works
Shi, Y., Ren, X., Cao, S., Chen, X., Yuan, B., da Costa, F. H. B., Rodriguez-Rosario, A. E., Corona, A., Michikawa, C., Veeramachaneni, R., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006666 · Cited by 42 · see citing works
The TP53 tumor suppressor gene: From molecular biology to clinical investigations
Baliakas, P., & Soussi, T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20106 · Cited by 45 · see citing works
Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
Chasov, V. V., Zaripov, M. M., Mirgayazova, R., Khadiullina, R., Zmievskaya, E., Ganeeva, I., Valiullina, A. K., Rizvanov, A. A., & Bulatov, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.707734 · Cited by 41 · see citing works
Exploring the Therapeutic Potential of Ganoderma lucidum in Cancer
Cancemi, G., Caserta, S., Gangemi, S., Pioggia, G., & Allegra, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041153 · Cited by 41 · see citing works
Berendsen, M. R., Stevens, W. B. C., van den Brand, M., van Krieken, J. H., & Scheijen, B. (2020) · Cancers · doi:10.3390/cancers12123553 · Cited by 40 · see citing works
Alemi, F., Sadigh, A. R., Malakoti, F., Elhaei, Y., Ghaffari, S. H., Maleki, M., Asemi, Z., Yousefi, B., Targhazeh, N., & Majidinia, M. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30573 · Cited by 41 · see citing works
Yang, Z., Sun, J. K., Lee, M. M., & Chan, M. K. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005068 · Cited by 38 · see citing works
Wang, X., Yang, J., Yang, W., Sheng, H., Jia, B., Peng, C., Xu, S., Hong, X., Jiang, C., Yang, Y., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.10.026 · Cited by 41 · see citing works
TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer
Zhang, Z., Hao, R., Guo, Q., Zhang, S., & Wang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.759154 · Cited by 40 · see citing works
Patterns and trends in melanoma mortality in the United States, 1999–2020
Didier, A. J., Nandwani, S. V., Watkins, D., Fahoury, A., Campbell, A. T., Craig, D. J., Vijendra, D. G., & Parquet, N. (2024) · BMC Cancer · doi:10.1186/s12885-024-12426-z · Cited by 38 · see citing works
Dietary Flavonoids in p53—Mediated Immune Dysfunctions Linking to Cancer Prevention
Siddiqui, S. S., Rahman, S., Rupasinghe, H. P. V., & Vazhappilly, C. G. (2020) · Biomedicines · doi:10.3390/biomedicines8080286 · Cited by 36 · see citing works
TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients
Sacconi, A., Donzelli, S., Pulito, C., Ferrero, S., Spinella, F., Morrone, A., Rigoni, M., Pimpinelli, F., Ensoli, F., Sanguineti, G., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01708-6 · Cited by 36 · see citing works
Tissues and Tumor Microenvironment (TME) in 3D: Models to Shed Light on Immunosuppression in Cancer
Ho, T., & Msallam, R. (2021) · Cells · doi:10.3390/cells10040831 · Cited by 37 · see citing works
An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53
Huang, Y., Jiao, Z., Fu, Y., Hou, Y., Sun, J., Hu, F., Yu, S., Gong, K., Liu, Y., & Zhao, G. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116121 · Cited by 33 · see citing works
Nel, A. E. (2023) · Environmental Research · doi:10.1016/j.envres.2022.114580 · Cited by 34 · see citing works
Ji, J. H., Ha, S. Y., Lee, D., Sankar, K. N., Koltsova, E. K., Abou‐Alfa, G. K., & Yang, J. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087640 · Cited by 34 · see citing works
Pi, X., Yan, D., Xu, Y., Pan, M., Wang, Z., Chang, M., & Qi, Z. (2024) · Aquaculture · doi:10.1016/j.aquaculture.2024.741615 · Cited by 34 · see citing works
Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe
Asl, E. R., Rostamzadeh, D., Duijf, P. H. G., Mafi, S., Mansoori, B., Barati, S., Cho, W. C. S., & Mansoori, B. (2023) · Life Sciences · doi:10.1016/j.lfs.2022.121361 · Cited by 34 · see citing works
TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19
Harford, J. B., Kim, S. S., Pirollo, K. F., & Chang, E. H. (2022) · Viruses · doi:10.3390/v14040739 · Cited by 32 · see citing works
Shi, C., Liu, S., Tian, X., Wang, X., & Gao, P. (2021) · BMC Cancer · doi:10.1186/s12885-021-08765-w · Cited by 31 · see citing works
Advances on Innate Immune Evasion by Avian Immunosuppressive Viruses
Wang, H., Li, W., & Zheng, S. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901913 · Cited by 31 · see citing works
The Wheel of p53 Helps to Drive the Immune System
Łasut-Szyszka, B., & Rusin, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087645 · Cited by 31 · see citing works
TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress
Zhu, K., Su, F., Yang, J., Xiao, R., Wu, R.-Y., Cao, M.-Y., Ling, X., & Zhang, T. (2024) · Molecular Biology Reports · doi:10.1007/s11033-023-09097-7 · Cited by 30 · see citing works
Haq, A. T. A., Yang, P., Jin, C. A., Shih, J., Chen, L., Tseng, H., Chen, Y., Weng, Y., Wang, L., Snyder, M. P., et al. (2024) · Theranostics · doi:10.7150/thno.92922 · Cited by 30 · see citing works
Temaj, G., Chichiarelli, S., Telkoparan‐Akillilar, P., Saha, S., Nuhii, N., Hadžiselimović, R., & Saso, L. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116332 · Cited by 33 · see citing works
Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies
Denisova, E., Westphal, D., Surowy, H., Meier, F. E., Hutter, B., REIFENBERGER, J., Rütten, A., Schulz, A., Sergon, M., Ziemer, M., et al. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00347-z · Cited by 29 · see citing works
The potential roles of p53 signaling reactivation in pancreatic cancer therapy
Ou, A., Zhao, X., & Lu, Z. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188662 · Cited by 29 · see citing works
Shifting the paradigms for tumor suppression: lessons from the p53 field
Barnoud, T., Indeglia, A., & Murphy, M. E. (2021) · Oncogene · doi:10.1038/s41388-021-01852-z · Cited by 29 · see citing works
Chauhan, S., Jaiswal, S., Jakhmola, V., Singh, B. P., Bhattacharya, S., Garg, M., & Sengupta, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216766 · Cited by 28 · see citing works
Luo, K., Qian, Z., Jiang, Y., Lv, D., Zhu, K., Shao, J., Hu, Y. C., Lv, C., Huang, Q., Gao, Y., et al. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107078 · Cited by 28 · see citing works
Xiao, X., Guo, L., Dai, W., Yan, B., Zhang, J., Yuan, Q., Zhou, L., Shan, L., & Efferth, T. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115167 · Cited by 27 · see citing works
Targeting p53 for immune modulation: Exploring its functions in tumor immunity and inflammation
Wu, H. H., Leng, S., Eisenstat, D. D., Sergi, C. M., & Leng, R. P. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217614 · Cited by 26 · see citing works
Identification of lysosomal genes associated with prognosis in lung adenocarcinoma
Li, H., Sha, X., Wang, W., Huang, Z., Zhang, P., Liu, L., Wang, S., Zhou, Y., He, S., & Shi, J. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-14 · Cited by 26 · see citing works
The Epigenetic Regulation of Nonhistone Proteins by SETD7: New Targets in Cancer
Chiang, C., Yang, H., Zhu, L., Chen, C., Chen, C., Zuo, Y., & Zheng, D. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.918509 · Cited by 25 · see citing works
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma
Manfredi, G. F., Celsa, C., John, C., Jones, C., Acuti, N., Scheiner, B., Fulgenzi, C. A. M., Korolewicz, J., Pinter, M., Gennari, A., et al. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s291553 · Cited by 26 · see citing works
Genes, pathways and vulvar carcinoma - New insights from next-generation sequencing studies
Zięba, S., Chechlińska, M., Kowalik, A., & Kowalewska, M. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.05.034 · Cited by 25 · see citing works
Santos‐Terra, J., Deckmann, I., Fontes‐Dutra, M., Schwingel, G. B., Bambini-Júnior, V., & Gottfried, C. (2021) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.10141 · Cited by 24 · see citing works
A Brief Review on Chemoresistance; Targeting Cancer Stem Cells as an Alternative Approach
Toledo, B., González-Titos, A., Hernández-Camarero, P., & Perán, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054487 · Cited by 24 · see citing works
TP53 R273C Mutation Is Associated With Poor Prognosis in LGG Patients
Zhang, J., Liu, M., Fang, Y., Li, J., Chen, Y., & Jiao, S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.720651 · Cited by 23 · see citing works
Identification of miR-30c-5p microRNA in Serum as a Candidate Biomarker to Diagnose Endometriosis
Chico-Sordo, L., Ruiz-Martínez, T., Toribio, M., González-Martín, R., Spagnolo, E., Domı́nguez, F., Hernández, A., & García-Velasco, J. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031853 · Cited by 24 · see citing works
Kim, A., Lim, S. M., Kim, J.-H., & Seo, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.598671 · Cited by 23 · see citing works
CD80 expression is upregulated by TP53 activation in human cancer epithelial cells
Scarpa, M., Marchiori, C., Scarpa, M., & Castagliuolo, I. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1907912 · Cited by 22 · see citing works
Autoantibodies to tumor-associated antigens in lung cancer diagnosis
Zhang, X., Liu, M., Zhang, X., Wang, Y., & Dai, L. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2020.08.005 · Cited by 22 · see citing works
A Bibliometric Analysis of Triptolide and the Recent Advances in Treating Non–Small Cell Lung Cancer
Yang, Q., Zhai, X., & Lv, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.878726 · Cited by 22 · see citing works
Mutant p53 as an Antigen in Cancer Immunotherapy
Sobhani, N., D’Angelo, A., Wang, X., Young, K. H., Generali, D., & Li, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114087 · Cited by 22 · see citing works
Targeting Oncoimmune Drivers of Cancer Metastasis
Kudo‐Saito, C., Ozaki, Y., Imazeki, H., Hayashi, H., Masuda, J., Ozawa, H., & Ogiwara, Y. (2021) · Cancers · doi:10.3390/cancers13030554 · Cited by 21 · see citing works
Advancements in p53-Based Anti-Tumor Gene Therapy Research
Peng, Y., Bai, J., Li, W., Su, Z.-D., & Cheng, X.-Y. (2024) · Molecules · doi:10.3390/molecules29225315 · Cited by 21 · see citing works
Wang, J., Tian, Y., Zhu, G., Li, Z., Wu, Z., Wei, G., Zhuang, L.-M., Li, Z., Chen, X., Zhang, X., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107817 · Cited by 21 · see citing works
Zhang, L., Hou, N., Chen, B., Kan, C., Han, F., Zhang, J., & Sun, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.908772 · Cited by 21 · see citing works
Kim, S. S., Harford, J. B., Moghe, M., Doherty, C. L., & Chang, E. H. (2022) · Cells · doi:10.3390/cells11213434 · Cited by 21 · see citing works
A new strategy for the treatment of intracerebral hemorrhage: Ferroptosis
Sun, K. Y., Bai, X. Y., Zhang, L., ZHANG, X. Y., Hu, Q., Song, Y., Qiang, R. R., Zhang, N., Zou, J. L., Yang, Y. L., et al. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114961 · Cited by 21 · see citing works
Amplifying Tumor–Stroma Communication: An Emerging Oncogenic Function of Mutant p53
Capaci, V., Mantovani, F., & Sal, G. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.614230 · Cited by 21 · see citing works
Li, S., Gao, J., Xu, Q., Zhang, X., Huang, M., Dai, X., Huang, K., & Liu, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693314 · Cited by 21 · see citing works
Ye, Y., Zhao, Q., Wu, Y., Wang, G., Huang, Y., Sun, W., & Zhang, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.989719 · Cited by 20 · see citing works
Ding, Y., Xue, M., Tang, Q., Wang, L., Ding, H.-Y., Li, H., Gao, C., & Yu, W. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i37.5403 · Cited by 20 · see citing works
RNA nanomedicine in liver diseases
Bakrania, A. K., Mo, Y., Zheng, G., & Bhat, M. (2023) · Hepatology · doi:10.1097/hep.0000000000000606 · Cited by 20 · see citing works
- Authors
- Blagih, J., Buck, M. D., & Vousden, K. H.
- Affiliations
- The Francis Crick Institute (GB)
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2020-03-01
- Volume
- 133
- Issue
- 5
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W3009145316
- Cited by
- 333
- References
- 195
- Citations by year
- 2026: 27 · 2025: 48 · 2024: 63 · 2023: 63 · 2022: 63 · 2021: 51 · 2020: 18
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Cell Science (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- The Francis Crick Institute (cc-by)
- Funders
- Cancer Research UK (C596/A26855, FC001557)
- Francis Crick Institute
- Medical Research Council (FC001557)
- Wellcome Trust (FC001557)
- Canadian Institutes of Health Research
- European Molecular Biology Organization (ALTF 1096-2018)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- p53, antitumor immunity, immune evasion, TP53 mutation, myeloid cells, T cells, tumor progression, cancer immunotherapy, cancer cells
- MeSH terms
- Humans, Immunity, Mutation, Neoplasms, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
